Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion in cash, securing access to proprietary circular RNA technology for in vivo cell engineering in autoimmune diseases and oncology....
null Novartis is reinforcing its commitment to acquiring early-stage pipeline assets and clinical-stage candidates, even as the pharmaceutical giant faces intensifying competition for late-stage drug...
Mubadala Capital has sold its minority stake in Arcadia Consumer Healthcare to funds managed by Bansk Group, marking the end of a four-year partnership that tripled the platform's revenue and...
Merck & Co. has terminated acquisition discussions with Revolution Medicines after failing to agree on price for a potential $28-32 billion deal, triggering a 20% drop in Revolution's shares and...